First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)A. Gazzah, N. Stjepanovic,M.H. Ryu, J. Tabernero,J.C. Soria,P. Bedard,Y.K. Kang,R. Bahleda, H. Guillemin-Paveau,C. Henry, L. Hatteville, C. Zilocchi,B. Demers,C. HierroEuropean Journal of Cancer（2016）引用 9|浏览9暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
